On June 30, Johnson & Johnson (NYSE:JNJ) announced that it has completed the divestiture of its Ortho-Clinical Diagnostics business to The Carlyle Group (CG) for approximately $4B, subject to customary adjustments. Under the terms of the transaction, The Carlyle Group has acquired the Ortho-Clinical Diagnostics business, a global provider of solutions for screening, diagnosing, monitoring and confirming diseases. The Ortho-Clinical Diagnostics business generated net sales of approximately $1.9B in 2013. Johnson & Johnson (NYSE:JNJ) net profit margin is 20.90% and weekly performance is 1.22%. On last trading day company shares ended up $105.87. Analysts mean target price for the company is $105.02. Johnson & Johnson (NYSE:JNJ) distance from 50-day simple moving average (SMA50) is 4.27%.
On June 12, 2014, VIVUS, Inc. (NASDAQ:VVUS) announced that it has filed a lawsuit in the U.S. District Court for the District of New Jersey against Actavis Laboratories FL, Inc., Actavis, Inc., and Actavis PLC, collectively referred to as Actavis. VIVUS, Inc. (NASDAQ:VVUS) shares advanced 0.38% in last trading session and ended the day on $5.38. VVUS Gross Margin is 87.70% and its return on assets is -32.10%. VIVUS, Inc. (NASDAQ:VVUS) quarterly performance is -11.59%.
On June 13, 2014, Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) held 2014 Annual Meeting of Stockholders. At the annual meeting, our stockholders (i) elected each of the director nominees named below to our Board of Directors to serve until the next annual meeting of stockholders and until their respective successors are elected and qualified or until their earlier resignation or removal; (ii) approved, on a non-binding, advisory basis, the compensation of our named executive officers, as disclosed in the proxy statement for the annual meeting; and (iii) ratified the appointment of KPMG LLP as our independent auditors for the fiscal year ending December 31, 2014. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) shares moved down -1.02% in last trading session and was closed at $5.80, while trading in range of $5.80 – $5.95. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) year to date (YTD) performance is -0.85%.
On June 25, 2014, the stockholders of Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) approved, at the Company’s 2014 Annual Meeting of Stockholders, the adoption of the ARIAD Pharmaceuticals, Inc. 2014 Long-Term Incentive Plan (“LTIP”). A brief description of the LTIP is set forth in the Company’s definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission (the “SEC”) on May 9, 2014, under the heading “Proposal 3: Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) ended the last trading day at $6.39. Company weekly volatility is calculated as 2.35% and price to cash ratio as 6.52. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) showed a positive/negative weekly performance of 1.27%.
On June 11, BASF SE (ADR) (OTCMKTS:BASFY)announced new investments and solutions that will help growers and partners in North America drive yields and efficiency. BASF will invest more than EUR200M, or $270M, to expand production capacity for key herbicides dicamba and DMTA at the Beaumont, Texas site as well as upgrade production at the Hannibal, Missouri site. With capacities expected to be on line in 2016/17, the expansions will serve to meet the growing demand for BASF’s diverse herbicide portfolio, which features nine different modes of action and multi-year rotational plans in order to ensure effective, flexible and durable weed control. BASF SE (ADR) (OTCMKTS:BASFY) shares moved up 0.44% in last trading session and was closed at $117.01, while trading in range of $116.17 – $117.07.